CARDINAL HEALTH INC

CAH

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Driehaus Capital Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 508,093Value: $12.3M

**Signal Note: Driehaus Capital initiates CAH position** Driehaus Capital's new $12.3M position in Cardinal Health (CAH) suggests conviction in the healthcare distributor's valuation or operational recovery, though this represents a pivot away from pure biotech into healthcare infrastructure. The signal may reflect positioning ahead of Cardinal's earnings cycle or confidence in margin expansion from GLP-1 drug distribution tailwinds, given the company's exposure to high-volume specialty pharmaceutical channels.

Deerfield ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

TNDM2 funds NUVL2 funds VEEV2 funds VCYT2 funds PODD2 funds NBIX2 funds BBNX2 funds TMDX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Cardinal Health (CAH) Deerfield Management's $1.8M initiation in CAH signals conviction in healthcare distribution fundamentals, likely driven by margin recovery in pharmaceutical distribution and potential upside from GLP-1 demand normalization post-2024. The position size is modest relative to Deerfield's typical check sizes, suggesting this is a tactical exposure rather than a major thesis bet, possibly hedging broader healthcare services exposure or positioning for Q1 2025 earnings inflection.